PDCD1 and neoplasm: Although treatment with PD-1/PD-L1 inhibitor monotherapy provides improved responses, prolonged survival and fewer toxicities compared with conventional therapies in many tumour types, a significant proportion of patients do not respond or eventually relapse on treatment due to secondary or acquired resistance [2, 5–8].